Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combinationwith Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma:SUCCESSOR-2
Phase 3
Recruiting
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-jRCT2071230095
- Lead Sponsor
- Engelhardt Brian
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
Participant has documented diagnosis of Multiple Myeloma and measurable disease.
Participant has received at least 1 prior line of anti-myeloma therapy.
Participant must have received prior treatment with lenalidomide and at least 2 cycles of
an anti-CD38 monoclonal antibody.
Exclusion Criteria
Participant who has had prior treatment with mezigdomide or carfilzomib.
Participant has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating
study intervention.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression-free survival
- Secondary Outcome Measures
Name Time Method Overall Survival, Overall Response, Very good partial response, Complete response, Time to Response, Duration of Response, Time to Progression, Time to Next Treatment, Progression-free Survival 2, adverse events